Nvidia Says BioNeMo Framework Will Advance Drug Discovery

Dow Jones11-19

By Connor Hart

Nvidia said companies across industries are adopting its open-source BioNeMo framework, which offers computing tools designed to help artificial intelligence advance drug discovery and accelerate molecule design.

These companies, from sectors including pharma, biotech and academia, include Argonne National Laboratory, Roche Group's Genentech and Weights & Biases, the tech company said Monday. More than 200 users have integrated the framework into their workflows.

The framework uses accelerated computing infrastructure to reduce costs, increase scale and speed up drug discovery workflows by providing insights from biomolecular data, the company said.

Vice President of healthcare Kimberly Powell said recent Nobel Prize wins in chemistry demonstrate AI and advanced computing ability to contribute to the pharmaceutical industry. "To help unravel the complexities of biological systems, we've introduced the open-source BioNeMo Framework, which will enable researchers world-wide to accelerate the development of life-saving treatments," she said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

November 18, 2024 14:11 ET (19:11 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment